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Abstract
Background: In 2012, as a pilot for Botswana’s national Xpert MTB/RIF (Xpert) rollout plans, intensified tuberculosis
(TB) case finding (ICF) activities were strengthened at 22 HIV treatment clinics prior to phased activation of 13 Xpert
instruments. Together, the strengthened ICF intervention and Xpert activation are referred to as the “Xpert
package”.
Methods: The evaluation, called the Xpert Package Rollout Evaluation using a Stepped-wedge design (XPRES), has
two key objectives: (1) to compare sensitivity of microscopy-based and Xpert-based pulmonary TB diagnostic
algorithms in diagnosing sputum culture-positive TB; and (2) to evaluate impact of the “Xpert package” on all-cause,
6-month, adult antiretroviral therapy (ART) mortality. A pragmatic, stepped-wedge cluster-randomized trial design
was chosen. The design involves enrollment of three cohorts: (1) cohort R, a retrospective cohort of all study clinic
ART enrollees in the 24 months before study initiation (July 31, 2012); (2) cohort A, a prospective cohort of all
consenting patients presenting to study clinics after study initiation, who received the ICF intervention and the
microscopy-based TB diagnostic algorithm; and (3) cohort B, a prospective cohort of all consenting patients
presenting to study clinics after Xpert activation, who received the ICF intervention and the Xpert-based TB
diagnostic algorithm. TB diagnostic sensitivity will be compared between TB culture-positive enrollees in cohorts A
and B. All-cause, 6-month ART-mortality will be compared between cohorts R and B. With anticipated cohort R, A,
and B sample sizes of about 10,131, 1,878, and 4,258, respectively, the study is estimated to have >80 % power to
detect differences in pre-versus post-Xpert TB diagnostic sensitivity if pre-Xpert sensitivity is ≤52.5 % and post-Xpert
sensitivity ≥82.5 %, and >80 % power to detect a 40 % reduction in all-cause, 6-month, ART mortality between
cohorts R and B if cohort R mortality is ≥13/100 person-years.
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Discussion: Only one small previous trial (N = 424) among ART enrolees in Zimbabwe evaluated, in a secondary
analysis, Xpert impact on all-cause 6-month ART mortality. No mortality impact was observed. This Botswana trial,
with its larger sample size and powered specifically to detect differences in all-cause 6-month ART mortality,
remains well-positioned to contribute understanding of Xpert impact.
Trial registration: Retrospectively registered at ClinicalTrials.gov: NCT02538952.
Keywords: Xpert MTB/RIF, Diagnostic accuracy, Sensitivity, Antiretroviral therapy, People living with HIV, Mortality,
Stepped-wedge cluster randomized trial, Botswana
Background
In Botswana, as in the rest of sub-Saharan Africa,
undiagnosed tuberculosis (TB) or TB diagnosed late in
the course of disease is thought to be the most common
cause of death among persons living with HIV (PLHIV),
whether they are receiving antiretroviral therapy (ART)
or not, with TB accounting for about 40 % of deaths ac-
cording to a recent meta-analysis of pathological autopsy
studies [1]. Although antiretroviral therapy (ART) re-
duces risk of all-cause mortality among PLHIV, early
mortality in the first 3–6 months after ART initiation re-
mains high in sub-Saharan Africa and is commonly due
to undiagnosed TB or TB diagnosed late [2–4].
Reasons for failure to diagnose TB early among PLHIV
can be categorized as patient-related or health facility-
related. Patient-related reasons include: (1) failure to
present to a health facility when symptoms arise, which
may be due to poor access to health care or cultural
norms that delay health-seeking behavior [5], and (2)
absence of TB symptoms among late presenters with
advanced immune suppression because TB symptoms
are dependent on both bacillary burden and immune
response [6].
Healthcare facility-related reasons for missed or late
TB diagnoses among PLHIV include: (1) failure of
healthcare workers (HCW) to screen for TB symptoms
[7–9]), (2) failure of HCWs to request sputum or other
diagnostic samples from symptomatic patients [10], (3)
inability to collect high quality sputa or other appropri-
ate diagnostic samples from symptomatic patients [11],
(4) insensitive TB diagnostics, with smear microscopy
alone having a sensitivity of about 45 % in diagnosing
culture-positive disease among PLHIV [12], (5) inability
to diagnose drug-resistant TB timeously [13], and (6)
long turn-around times for some TB diagnostic tests or
failure to return results to clinicians and patients [14].
In 2009, the commercial release of the Xpert MTB/
RIF assay (Xpert) for the GeneXpert platform repre-
sented an important breakthrough in TB diagnostics.
With features including sensitivity of about 79 % in diag-
nosing culture-positive TB from sputum samples among
PLHIV [15], significantly superior to smear microscopy
[12], ability to detect rifampicin resistance-conferring
mutations, capacity to run the test on sputum samples
within 100 min after brief sample processing, and minimal
laboratory training requirements, Xpert significantly ad-
vanced TB diagnostic capability for clinicians managing
PLHIV, especially in resource-limited settings (RLS) [16].
However, Xpert on its own, cannot solve all the facility-
level challenges to diagnosing TB [17]. Strengthening of
the entire TB symptom screening and diagnostic algo-
rithm is needed for Xpert to have maximum impact on
patient health outcomes in most RLS [17].
Therefore, in 2012, the Botswana Ministry of Health
(MOH) and the United States Centers for Disease
Control and Prevention (CDC), designed a package of
intensified TB case finding (ICF) interventions to be
rolled out prior to, and in coordination with, the phased
activation of 13 Xpert devices in support of 22 HIV care
and treatment clinics.
The package of ICF interventions included: (1) ensur-
ing the 22 HIV care and treatment clinics adopted the
World Health Organization (WHO)-recommended four-
symptom TB screen for adults (>12 years old as defined
by the HIV care and treatment program); (2) situating
trained TB case-finding nurses in all 22 facilities to im-
plement the screening and diagnostic algorithms; and (3)
training TB case-finding nurses and other health facility
personnel in both smear-microscopy-based and Xpert-
based TB diagnostic algorithms for adults and children.
The combination of the ICF interventions and rollout of
the Xpert device is referred to as the “Xpert package” in
this report.
To evaluate the accuracy of the new MOH-proposed
Xpert diagnostic algorithm and also the impact of the
whole Xpert package on patient outcomes, a pragmatic,
stepped-wedge cluster-randomized trial (CRT), referred
to as the Xpert Package Rollout Evaluation using a
Stepped-wedge design (XPRES), was initiated. In this
paper, the protocol-specified key study objectives, design
rationale, sample size, key procedures, and analytic
approaches are described. In addition, the evolution of
power estimates over time as real-time study enrollment
numbers became available, and key amendments to
study procedures, which were needed to adapt to oper-
ational challenges, are described.
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Methods
Key objectives
The first objective of the evaluation is to determine
whether the new MOH-recommended Xpert-based pul-
monary TB diagnostic algorithm (including Xpert testing
of sputum samples for all patients screening positive
(i.e., presumptive TB patients) and chest x-ray for Xpert-
negative presumptive TB patients) is more sensitive than
the pre-Xpert smear-microscopy-based algorithm (smear
microscopy and chest x-ray for smear-negative presump-
tive TB patients) in diagnosing culture-positive TB dis-
ease among adult PLHIV. Although it is expected that
the Xpert-based TB diagnostic algorithm will be both
more sensitive and more specific than the pre-Xpert al-
gorithm, superiority of the Xpert algorithm has not yet
been demonstrated in Botswana and thorough evalu-
ation of the accuracy of the new diagnostic algorithm is
important to guide future investments [18, 19].
The second objective is to evaluate the impact of the
whole Xpert package on all-cause mortality during the
first six months of ART, among adult PLHIV. With an
estimated 40 % of early ART deaths due to undiagnosed
TB or TB diagnosed late, the Xpert package could con-
ceivably reduce all-cause, 6-month ART mortality by en-
suring: (1) that all ART enrollees are appropriately
screened for TB symptoms before and during ART, and
(2) that presumptive TB patients have access to a sensi-
tive TB test (Xpert) and early TB treatment where war-
ranted [20]. Only one small trial (N = 424) in Zimbabwe
has previously aimed to examine the impact of Xpert-
versus microscopy-based TB diagnostic algorithms on 6-
month ART mortality [21]; no difference in early ART
mortality was noted between study arms, however, the
small sample size and high rates of empiric TB treat-
ment in both study arms limit study findings.
Study design rationale
A pragmatic stepped-wedge CRT design was chosen be-
cause: (1) Xpert device activation was most feasibly
achieved for an entire district TB laboratory, which often
served more than one health facility; this fact made an
individual randomized controlled trial (RCT) design less
desirable [19], (2) according to WHO guidance [22] and
MOH guidelines [23], the Xpert device was expected to
be beneficial for both patients and providers, and there-
fore it was considered ethically sub-optimal to imple-
ment a parallel group CRT, where certain district TB
labs and their associated clinics were denied access to
Xpert for an extended period of time [12, 24], (3) the
phased rollout of Xpert provided logistical advantages,
because it meant that a single site activation team, in
charge of training and activation of the Xpert device,
could sequentially initiate all study sites [24], (4) the
need for only a single site activation team reduced
projected study cost, (5) program managers and funders
were interested in assessing accuracy of the Xpert diag-
nostic algorithm in a real-world environment rather than
trying to assess accuracy in a tightly controlled research
environment, with limited external validity [25], (6) in a
real-world setting, the sequential rollout of an interven-
tion allows lessons learned during earlier steps to be ap-
plied during later steps, and (7) a stepped-wedge design
provides analysis options that allow for the control of
trends over time [26, 27].
Study design description
Figure 1 summarizes the study design. This step-wedge
design involved enrollment of three cohorts: (1) retro-
spective cohort (R), shaded in red in Fig. 1, (2) prospect-
ive cohort A (enrolled pre-Xpert device rollout), shaded
in yellow in Fig. 1, and (3) prospective cohort B (en-
rolled post-Xpert device rollout), shaded in green in
Fig. 1. For cohort R, all patients who initiated ART at
one of the 22 HIV clinics for the first time in the
24 months before study start (i.e., before July 31, 2012),
were eligible for enrollment. For cohort A, all patients
who attended one of the 22 HIV clinics for the first time
after study start (July 31, 2012), but before Xpert device
rollout, were eligible for enrollment. For cohort B, all pa-
tients who attend one of the 22 HIV clinics for the first
time after Xpert device rollout were eligible.
To answer the first primary study question, sensitivity
of the pre-Xpert TB diagnostic algorithm in prospective
cohort A will be compared with the post-Xpert algo-
rithm sensitivity in prospective cohort B. Figure 2 de-
scribes the differences in TB diagnostic algorithms
between cohorts A and B and how sensitivity propor-
tions will be determined.
To meet the second key study objective (comparison
of pre- versus post-Xpert package all-cause ART mortal-
ity), all-cause 6-month ART mortality rates will be com-
pared between the retrospective cohort (cohort R) and
the post-Xpert prospective cohort (cohort B). Since the
cohorts being compared (cohorts R and B) do not over-
lap in a phased manner that would allow for controlling
for secular trends according to analytic approaches rec-
ommended by Moulton et al [26] or Hussey & Hughes
[27], this analysis approach is best characterized as a be-
fore and after comparison. However, secondary analyses,
comparing 6-month ART mortality, and other ART out-
comes, between cohorts A and B will make use of the
stepped-wedge portion of the trial and analytic ap-
proaches recommended by Moulton et al [26] and
Hussey & Hughes [27] to control for secular trends.
Interventions
As described above, Fig. 2 illustrates the differences be-
tween the microscopy-based algorithm used in cohort A
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(pre-Xpert device rollout), and the Xpert-based algo-
rithm used in cohort B (post - Xpert device rollout).
For the second key question, comparing all-cause 6-
month ART mortality in cohort R with cohort B, Table 1
summarizes the differences between cohort R and B in
terms of TB case finding and patient management activ-
ities. Notably, in addition to implementing ICF activities,
study nurses were responsible for tracing prospectively
enrolled patients (patients in cohorts A and B) who were
≥1 day late for a clinic appointment through up to five
telephone calls and two home visits to return patients to
HIV care. Indicators measuring compliance with all in-
terventions, including implementation of the appropriate
TB diagnostic algorithm and the tracing intervention,
will help inform discussions of causal pathways during




The main reason for selecting the 22 facilities in Table 2
is that they are considered by study investigators and
MOH to be representative of facilities in Botswana in
terms of TB case finding capacity and ART service deliv-
ery. Study facilities consist of five district hospitals and
17 primary healthcare clinics (PHCs). Other advantages
of choosing these facilities are: (1) on average they had
anticipated high patient enrollment rates (at 33 patients/
month/clinic), which helped meet the desired study
power (see below), (2) one clinic (Gantsi, in Western
Botswana) is estimated to have high prevalence of multi-
drug resistant TB among HIV clinic enrollees and so
could benefit from early rollout of the Xpert device per
WHO recommendations [22], and (3) all 22 clinics had
at least one year’s experience in providing ART services
by the time of study start. Table 2 summarizes the study
facilities chosen for XPRES.
Study patients
For the retrospective cohort, all patients starting ART in
the 24 months before study start, except for prisoners,
were eligible for chart abstraction to estimate all-cause
ART mortality rates. For the prospective cohorts (A and
B), all patients, who met consent requirements, register-
ing for HIV care for the first time at the facility in the
19 months after study start, were eligible for enrollment,
except for prisoners. Prisoners were excluded because it
would be difficult to obtain comprehensive retrospective
cohort data for cohort R, due to frequent unscheduled
prisoner movement during incarceration, and difficult to
retain prisoners in cohorts A and B for the study’s dur-
ation. Children (<12 years of age) were eligible for pro-
spective enrollment, if their assent and guardian’s
consent were provided, because secondary study ques-
tions aim to estimate Xpert algorithm sensitivity for chil-
dren and its impact on pediatric ART outcomes.
Randomization procedures
Because some of the clinics use the same TB diagnostic
facility, Xpert activation was simultaneous for these
clinic consortiums (Table 2). For scheduling purposes
and because clinic staff rotations occurred at the end of
Fig. 1 Study design for the Xpert package rollout evaluation using a stepped wedge design (XPRES)
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Fig. 2 Comparison of pre-X pert and Xpert-based TB diagnostic algorithms in adults
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calendar months, each step in the stepped-wedge design
needed to be equivalent to one calendar month. In
addition, because the MOH and partners wanted the 13
Xpert devices to be operational and serving patients in
nine months rather than 13 months, there was a need to
initiate two Xpert devices during a single step for four of
the nine steps. Taking into consideration constraints in
Xpert device assignments to clinics (see Table 2 and
Fig. 1), there were 9! (362,880) possible permutations of
the order of Xpert rollout. The study statistician ran-
domly selected one of these permutations [28].
Sample size and power—first key objective
Funding availability limited the prospective enrollment
duration to 19 months at the 22 study facilities. MOH
monitoring data reported an average of 23 new ART-
eligible patients enrolling in each facility per month and
investigators estimated there were 10 new ART-
ineligible patients enrolled per month at each facility
(i.e., potentially 33 study-eligible patients/month/clinic).
To be conservative with sample size estimates, we as-
sumed that only 70 % of study-eligible patients would
agree to prospective enrollment in the study (i.e., 23
study patients/month/clinic), giving anticipated cohort A
and B sample sizes of 3,266 and 6,348, respectively (N =
9,614). Since the vast majority of patients (>99 %) at
these study clinics were adults (≥12 years old), for the
purpose of sample size calculations, we assumed all
9,614 prospective enrollees would be adults.
Based on a published meta-analysis, we estimated that
about 49 % of new adult HIV clinic enrollees would
screen positive for TB [29], and that about 33 % of those
screening positive would have culture-confirmed TB,
giving an overall active TB prevalence among adult study
enrollees of about 16.2 % [30–35]. Our literature review
suggested true active TB prevalence among adult PLHIV
entering HIV care ranged from 7.1 % in Ethiopia [34] to
31.5 % in South Africa [33]; since Botswana has a higher
TB case notification rate (about 470/100,000 population)
than Ethiopia (about 224/100,000 population) but a
lower TB case notification rate than South Africa (about
860/100,000 population), our estimate of adult active TB
prevalence of 16.2 % at HIV care entry in Botswana was
considered reasonable [36–38]. Further literature review
suggested that the pre-Xpert, microscopy-based TB diag-
nostic algorithm sensitivity might be as high as 62.5 %
Table 1 Comparison of TB case finding and patient management interventions for PLHIV in the retrospective and prospective cohorts
Retrospective (R) Prospective pre-Xpert (A) Prospective post-Xpert (B)
TB screening algorithm for
adults
1. Cough of any duration
2. Fever of any duration
3. Shortness of breath
4. Chest pain
5. Haemoptysis
6. Loss of appetite









3. Loss of weight
4. Night sweats
Number of sputa collected
from patients suspected of
having TB
2 spot sputa 4 (2 spot sputa on day 1, 1 morning
sputum on day 2, and one spot sputum
on day 2)
4 (2 spot sputa on day 1, 1 morning




Estimated to be low High High
Specialized TB case finding
nurses support TB case
finding activities
No Yes Yes
Regular training for clinic




Microscopy + chest X-ray for
smear-negative suspects
Microscopy + chest X-ray for smear-
negative suspects
Xpert + chest X-ray for Xpert-negative
suspects
Gold standard TB
diagnostic test (MGIT) at
national TB reference
laboratory (NTRL)
Infrequent utilization of MGIT
liquid TB culture at NTRL
MGIT liquid TB culture for all patients
suspected of having TB. Prior to culture,
fluorescent microscopy was conducted
at NTRL.
MGIT liquid TB culture for all patients
suspected of having TB. Prior to culture,
fluorescent microscopy was conducted
at NTRL.
TB drug resistance Infrequent requests for TB drug
resistance tests.
All positive MGIT TB cultures received: (1)
LPA, (2) Phenotypic culture-based DST.
All positive MGIT TB cultures received: (1)
LPA, (2) Phenotypic culture-based DST.
Patient tracing
interventions in place
Irregular attempts to trace
patients late for clinic
appointments through telephone
calls and home visits.
Tracing of patients late for clinic
appointments through telephone calls
and home visits.
Tracing of patients late for clinic
appointments through telephone calls
and home visits.
Abbreviations: ICF intensified TB Case Finding, TB tuberculosis, MGIT mycobacteria growth indicator tubes, LPA line probe assay, DST drug susceptibility testing
Auld et al. BMC Infectious Diseases  (2016) 16:606 Page 6 of 14
[34], and that Xpert algorithm sensitivity among symp-
tomatic PLHIV could be about 82.5 % based on data
from a recent multi-country Xpert accuracy study [12].
To estimate power, data were simulated according to the
stepped-wedge design, using the beta-binomial model to
induce the intra-cluster correlation coefficient. One thou-
sand datasets were simulated and a mixed model appropri-
ate for the stepped-wedge design fit to the data, as
described by Hussey and Hughes [27], that included fixed
effects for time and intervention condition (0 for time
points before Xpert implementation and 1 afterward), and
a random effect for the clinic, to take into account
between-clinic variability. For protocol-specified sample
sizes (N = 9,614), and assuming culture-positive TB preva-
lence of 16.2 % at study entry, and pre-versus post-Xpert
sensitivity comparisons of 62.5 % vs. 82.5 %, we had 99.6 %
power. In multiple simulations, pre-Xpert sensitivity was
varied from 55 % to 62.5 % and post-Xpert sensitivity from
70 % to 82.5 % and the study had >80 % power to detect
the intervention effect across all simulated scenarios.
After study initiation, monitoring data, prepared by
study nurse supervisors during supervision visits, re-
vealed that actual monthly HIV clinic enrollment
numbers were lower than expected (about 21 pa-
tients/clinic/month instead of 33 patients/clinic/
month). In addition, study nurses were only able to
enroll about 72 % of study-eligible patients at the
clinic, mostly because patients were not willing to
wait while the study nurse completed enrollment of
other patients, a process which took about 1 h/enrol-
lee. Therefore, prospective enrollment occurred at about
15/month instead of the protocol-specified 23/month. In
addition, the proportion of adult patients screening posi-
tive for TB at prospective cohort enrollment was lower
than expected (24 % instead of 49 %), and the proportion
of those screening positive, who were diagnosed with
culture-positive TB, was lower than expected (17 % in-
stead of 33 %), giving a much lower culture-positive TB
prevalence at enrollment than was originally expected
(about 4 % instead of 16 %).
Table 2 Selected study sites for the Xpert package rollout evaluation using a stepped-wedge design (XPRES)
District Fixed consortiums Clinic names Pre-study estimates of no.
new ART patients/month
Xpert location
Ngami (Maun) fixed triplet Letsholathebe II Memorial Hospital 36 1 × Lab Xpert
Ngami (Maun) Boseja Clinic 28
Ngami (Maun) Maun Clinic 28
Gaborone fixed pair Brodhurst Traditional Clinic 35 1 × Lab Xpert
Gaborone Bontleng Clinic 45
Francistown fixed pair Botswelelo Clinic 22 1 × Lab Xpert
Francistown Area W Clinic 22
Francistown single facility Nyangabgwe Referral Hospital 18 1 × Lab Xpert
Kweneng East-Molepolole fixed quadruplet Borakalalo Clinic 9 1 × POC Xpert
Kweneng East-Molepolole Kgosing Clinic 8
Kweneng East-Molepolole Molepolole Central Clinic 8
Kweneng East-Molepolole Phuth-kobo Clinic 8
Kweneng East-Mogoditsane single facility Nkoyaphiri Clinic 46 1 × POC Xpert
Palapye fixed pair Ext 3 Clinic 20 1 × POC Xpert
Palapye Lotsane Clinic 20
Bobirwa single facility Bobonong Primary Hospital 38 1 × Lab Xpert
Kanye single facility SDA Hospital 22 1 × Lab Xpert
Gantsi single facility Gantsi Clinic unknown* 1 × Lab Xpert
Kgatleng single facility Deborah Memorial Hospital 26 1 × Lab Xpert
Lobatse single facility Athlon Clinic 18 1 × Lab Xpert
Serowe District fixed pair Kadimo Clinic 12 1 × POC Xpert
Serowe District Serowe Clinic 12
Total (22 clinics) 479 13
Average per clinic 23
Abbreviations: POC point of care, Xpert Xpert MTB/RIF, lab laboratory, ART antiretroviral therapy
*Routine monitoring data on rate of enrollment of antiretroviral therapy patients was not available at the time of study initiation for this clinic
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Lower numbers of culture-positive TB cases/clinic/
month (1/clinic/month instead of 4/clinic/month)
resulted in inability to fit the stepped-wedge model
to all simulated datasets. Therefore, the power esti-
mation approach was simplified and Fisher’s Exact
Test for comparing two proportions (pre-and post-
Xpert) in SAS version 9.2. software (SAS Institute
Inc., Cary, NC) was used to estimate study power.
Power estimates were then adjusted for the expected
design effect to account for intra-cluster correlation.
For design effect calculations, an intra-class correl-
ation of 0.05 was assumed [28]. Input estimates for
TB prevalence at HIV care enrollment and TB diag-
nostic sensitivity were varied to understand impact
on study power (Fig. 3). As illustrated in Fig. 3,
sample size and TB prevalence shortfalls meant we
only had about 75.4 % power to detect the protocol-
specified difference in sensitivity (62.5 % vs. 82.5 %)
if active TB prevalence at enrollment was 4 %. How-
ever, we would have >80 % power to detect pre-
versus post-Xpert TB diagnostic sensitivities at a
culture-positive TB prevalence of 4 % if pre-Xpert
sensitivity was ≤52.5 % and post-Xpert sensitivity
≥82.5 % (Fig. 3). Because available National TB
Reference Laboratory (NTRL) monitoring data sug-
gested pre-Xpert TB diagnostic sensitivity was
≤52.5 % and Xpert sensitivity ≥82.5 %, the study was
considered still well powered to answer the first key
study question at quarterly reviews conducted by the
study sponsor.
Sample size and power—second key objective
To estimate power for the comparison of all-cause 6-
month mortality in the retrospective cohort (cohort R)
versus the post-Xpert prospective cohort (cohort B), the
approach of Moulton et al, suitable for stepped-wedge
trial designs, was chosen because these power estimates
were more conservative than those derived from a pre-
post sample size calculation [26]. Per this approach,
published formulae for the comparison of two rates in
an unmatched parallel group CRT [39] were adapted to
the stepped-wedge design as follows:
Zβ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
c−1ð Þ rc−rtð Þ2




where Zβ is the standard normal deviate corresponding
to the upper tail probability of β and β is the probability
of a Type II error; c is the number of clusters (study fa-
cilities) per arm, where, since this is a stepped-wedge
trial involving 22 clinics, 22/2 was used [26]; rc is the es-
timated true 6-month ART mortality rate in the pre-
intervention control phase (cohort R); rt is the estimated
true mortality rate in the post-intervention phase (co-
hort B); yc is the average number of person-years (PYs)
per clinic in the control phase, estimated as the average
retrospective cohort size per clinic (552) divided by two
since each patient commits 6 months of follow-up time
to the analysis; yt is average number of PYs per clinic in
the intervention phase, conservatively estimated as
the harmonic mean of PYs contributed by each study
Fig. 3 Figure showing power to detect a difference in TB diagnostic algorithm sensitivity pre- versus post-Xpert over a range of culture-positive
TB prevalence rates at study enrollment according to actual prospective cohort sample size (N = 6,136)
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site in cohort B, again assuming 6 months of follow-
up time per participant [26]; k is the estimated
between-cluster coefficient of variation of the true
rates in both the control and intervention phases, es-
timated as 0.2 [26]; Za/2 is the standard normal devi-
ate corresponding to the upper tail probability of a/2
where a is the probability of a Type I error.
Since a log-rank test statistic for intervention effect
calculated for a simulated stepped-wedge trial (ZSW) will
generally always be lower than the corresponding statis-
tic (ZE) for a parallel group trial, because allocation ra-
tios of patients to intervention or control status for
parallel group trials remain equal while for stepped-
wedge trials they are usually unequal, except at the mid-
point of the stepped-wedge design, the z-score in the
stepped-wedge trial formula (Zβ above) was divided by a
published estimate of ZE/ZSW (i.e., 1.2) prior to extrapo-
lating the z-score to a power estimate [26]. Similarly, for
Type 1 error of 5 %, instead of assuming a Zα/2 of 1.96,
an inflated estimate of 2.352 was used, per published
precedent [26].
Prior to study start, available data from Botswana sug-
gested that the documented all-cause early mortality
rates in the first 6 months of ART among adults were
about 15 deaths per 100 PYs [40], which was similar to
estimates from a meta-analyses of 18 programs in RLS
with active tracing programs (14.7/100 PY) [41]. Since
Botswana data, and available meta-analyses suggested
about 40 % of deaths among PLHIV were due to undiag-
nosed TB or TB diagnosed late, and given that interrupt-
ing ART during the first 6 months of therapy by missing
clinic appointments increases mortality risk [42, 43], it
was considered reasonable that the Xpert package plus
the tracing intervention might reduce mortality by about
40 % [2, 44]. According to protocol-specified sample
sizes, the study had >80 % power to detect a difference
in 6-month all-cause ART mortality between cohorts R
and B of 40 % if cohort R mortality was ≥10/100 PYs
(Fig. 4). According to anticipated actual sample sizes, the
study has >80 % power to detect a difference in 6-month
all-cause ART mortality between cohorts R and B of
40 % if cohort R mortality is ≥13/100 PYs (Fig. 4).
Study procedures related to first key objective
For prospective cohort enrollment, all new HIV clinic
enrollees were informed about the study, and if inter-
ested, offered the opportunity to enroll following the
Institutional Review Board (IRB)-approved consent
process. An enrollment questionnaire collected import-
ant baseline demographic and clinical information, and a
patient locator form was used to document telephone
numbers and home addresses for patient retention activ-
ities. Adult patients screening positive for TB were asked
to provide four sputa, two collected simultaneously the
day of enrollment (referred to as “spot” sputa), and two
the following day. Of the two sputa provided the second
day, one was a morning sputum prepared by the patient
soon after waking up, and the other a spot sputum pro-
vided upon arrival at the clinic. Additional file 1 shows a
poster used by study nurses to inform the patient how
to produce a good sputum. The poster also illustrates
important infection control precautions (e.g., preparing
Fig. 4 Power to detect a 40 % and 50 % difference in all-cause 6-month ART mortality between pre-Xpert retrospective and post-Xpert prospective
cohort enrollees over a range of pre-Xpert mortality rates
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spot sputa in a well-ventilated, but still private, “cough
spot” outside the clinic). If a patient screening positive
for TB was unable to spontaneously produce sputa,
MOH-recommended sputum-induction procedures were
encouraged if there were no contra-indications [23]. For
children <12 years old, who were unable to produce
sputa spontaneously and were too young for induction
(i.e., <5 years old), naso-gastric tube aspirates were rec-
ommended per MOH guidelines [23]; however, very few
children <5 were expected to enroll in the study.
Spot sputa numbers one and three were sent to the
on-site or peripheral district TB lab for: (1) smear mi-
croscopy, and (2) Xpert, if the Xpert device had been ac-
tivated by that time. Spot sputum 2 and the morning
sputum were sent to the NTRL for: (1) fluorochrome
acid fast bacilli (AFB) smear microscopy on concen-
trated specimens, (2) liquid culture in mycobacteria
growth indicator tubes, (3) confirmation of any myco-
bacterial growth as Mycobacterium tuberculosis (MTB)
or non-tuberculous mycobacteria through Ziehl-Neelsen
staining, blood agar plate, and immunochromatographic
assays, (4) line probe assay testing for isoniazid and ri-
fampicin resistance on MTB-positive cultures, and (5)
phenotypic culture-based drug susceptibility testing on
MTB-positive cultures. All test results were returned to
study nurses with recommended maximum turnaround
times from the time of sample collection to result return
to the nurse being four days for smear microscopy at the
peripheral lab, 10 days for flourochrome smear micros-
copy at the NTRL, two days for Xpert testing regardless
of Xpert location, and 49 days for liquid culture results
from the NTRL. Nurses were encouraged to inform pa-
tients of positive TB diagnoses the same day via phone,
although, if the patient was unreachable by phone, the
patient was informed at the next scheduled clinic
appointment.
For the first 17 months of study conduct, all prospect-
ively enrolled patients consented to 12 months of
follow-up but this was shortened to 6 months of follow-
up in December 2013 (17 months into study enroll-
ment), in an attempt to reduce burden on study nurses.
Study procedures related to second key objective
Enrollment of the retrospective cohort (cohort R) was
through chart abstraction of eligible patients who started
ART in the 24 months before study initiation at one of
the 22 study clinics. Chart abstraction procedures were
similar to procedures described in previous studies [45].
Data on important demographic and clinical characteris-
tics were abstracted to maximize opportunities to ex-
plore and control for confounding, when estimating
impact of the Xpert package on all-cause mortality.
Since loss to follow-up (LTFU) from ART can account
for as much as 75 % of all attrition (death plus LTFU) in
ART programs, and because incidence of death follow-
ing LTFU ranges from 20 % to 60 % and failure to adjust
mortality estimates for death among LTFU patients
could bias estimates of intervention effect [40, 46], tra-
cing patients LTFU was considered essential to answer
the second key question. Tracing for mortality ascertain-
ment purposes, was conducted through two methods in
all cohorts. Firstly, up to five telephone calls and two
home visits were used to determine outcomes of patients
LTFU; in the retrospective cohort this occurred follow-
ing documentation that the patient was >90 days late for
a scheduled appointment, whereas in the prospective co-
hort this tracing started the day following a missed ap-
pointment. Secondly, all patients that remained LTFU
following telephonic and home visit tracing activities
were searched for in Botswana’s national mortality
database.
Since about 2,429 (28 %) of 8,565 patients eligible for
the prospective cohort did not enroll due to logistical
constraints (see above), a protocol amendment was ap-
proved in April 2014, that allowed retrospective chart
abstraction of the missed prospective patients. By
abstracting key baseline data (e.g., baseline CD4 count)
and outcome data (e.g., vital status) on the 2,429 missed
patients, investigators will be able to: (1) estimate if the
prospective cohort is truly representative of new HIV
clinic enrollees at the 22 study sites during study con-
duct, and (2) use appropriate methods to explore effect
of non-response [47].
Analytic methods
For the first key study question, we will employ a mixed-
model approach similar to that presented by Hussey and
Hughes (2007) [27]. A generalized linear mixed model
will be fit to the data. The dependent variable is dichot-
omous, indicating whether the diagnostic algorithm de-
tected TB or not (only those with true TB detected by
liquid culture will be included in the sensitivity analysis).
A fixed effect for time will be included in the analysis to
adjust for any time trends that might bias the pre-post
comparison. A fixed effect for intervention condition (0
before Xpert implementation, 1 afterward) will also be
included and is the test of the intervention effect. A ran-
dom effect for clinic will be included to adjust for
between-clinic variation. The intervention effect will be
judged significant at p < 0.05 with a two-tailed test.
For the second key question, crude and multivariable
Cox proportional hazards regression models, accounting
for study design, will be fit to the data with a fixed effect
specified for intervention status, and random effect for
clinic [28]. Since there are three levels to the interven-
tion, with cohort R receiving standard of care, cohort A
receiving the ICF intervention, and cohort B receiving
the ICF intervention plus the Xpert diagnostic
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algorithm, intervention effect will be coded as a three-
level variable to represent the three study phases. Al-
though the protocol-specified primary question aims to
compare 6-month mortality in cohort R versus cohort B,
investigators will examine for any dose-response effect
across cohorts R, A, and B, which could add data to in-
form interpretation of causal pathways [48]. Importantly,
the analysis will need to control for trends over time.
Several reports from RLS, including Botswana [49], have
reported improvements in baseline health status at ART
initiation (e.g., higher median CD4 counts) and lower in-
cidence of 6-month ART mortality over successive an-
nual cohorts of ART enrollees. As described earlier,
because cohorts R and B do not overlap during the
stepped-wedge portion of this trial, a comparison of 6-
month mortality rates in cohorts R and B cannot make
use of the stepped-wedge design to control for secular
trends [26]. However, since most variation in 6-month
ART mortality over successive annual ART cohorts is
accounted for by changes in health status of ART enrol-
lees (e.g., changes in baseline CD4 count), incorporation
of these known risk factors for 6-month ART mortality
into the multivariable model may fully account for secu-
lar mortality trends [7, 50].
In a secondary analysis, that excludes cohort R, we will
compare 6-month ART mortality rates between cohorts
A and B using analytic methods described by Moulton
et al, fitting Cox proportional hazards models to the data
with the underlying time frame being time since July
2012 (initiation date for the stepped-wedge component
of the trial), fixed effect for intervention arm (Xpert de-
vice activation), and a random effect for clinic [26, 51].
We will also explore an alternate analytic approach, rec-
ommended by Hussey & Hughes, which utilizes a Poisson
model, including fixed effect for intervention and time
interval, and a random effect for cluster [27].
Ethical considerations
This research study was reviewed and approved by the
CDC IRB C, the Health Research and Development
Division of the Human Resource Development Council
(HRDC) in Botswana, and the University of Pennsylvania
IRB No.4. XPRES is registered at ClinicalTrials.gov (trial
registration no. NCT02538952).
Trial status
Prospective cohort enrollment started in July, 2012 and
was completed by the end of March 2014. Retrospective
cohort chart abstraction was complete by December
2015. Data entry is estimated to be complete by the end
of September 2016. Data analysis for the primary study
questions has not yet begun. Trial data will be reported
according to published guidelines for cluster-randomised
trials (Additional file 2).
Discussion
The over-arching purpose of this project is to improve TB
diagnostic and care services at 22 HIV care and treatment
clinics through phased rollout of (1) strengthened ICF sys-
tems, and (2) 13 Xpert devices, while simultaneously an-
swering important implementation science questions,
concerning Xpert operationalization and impact.
The stepped-wedge study design was chosen for a
number of reasons related to ethical, operational, and
analytic needs, as described in the method’s section.
During the course of study implementation, the oper-
ational advantages of the phased implementation ap-
proach have been particularly notable. In our RLS of
Botswana, the phased implementation approach has
allowed the limited human and financial resources to be
focused on smaller, more manageable pieces of the
whole project, one step at a time, rather than be spread
thinly across study sites, as would be required in a paral-
lel group CRT [19]. Analytically, the stepped-wedge de-
sign allows multiple opportunities for controlling trends
over time [26]. Potential disadvantages, when compared
with a parallel group CRT, include: (1) moderately lower
ability to assign causality to the intervention, and (2)
higher sample size requirements in most circumstances,
because of unequal allocation ratios for most of the dur-
ation of stepped-wedge trials [19]. The ethical, oper-
ational, and analytic advantages may help explain the
increasing popularity of the stepped-wedge evaluation
design, especially in RLS [24].
During trial conduct, several operational challenges
were experienced, mainly related to lower than expected
clinic enrolment rates, human resource constraints that
reduced ability to enroll all study-eligible patients in the
prospective cohort, and lower than expected prevalence
of culture-positive TB at clinic enrollment. The declining
HIV clinic enrolment rates probably reflect success of
the HIV treatment program in reaching HIV-infected
persons in prior years (i.e., during 2002–2011) [49], de-
clining HIV incidence rates [52], and expanding num-
bers of alternate HIV clinics at which patients can
receive care [49]. The study team probably over-
estimated the willingness of patients to wait at the clinic
for their turn to enroll in the study. However, in
response to the observation that 28 % of potentially
study-eligible patients were not being enrolled in the
prospective cohort, the study team wrote a protocol
amendment that allowed retrospective chart abstraction
for the missed prospective patients, which will allow
investigators to quantify any potential selection bias in-
curred by non-response. The lower than expected preva-
lence of culture-positive TB at HIV clinic enrollment
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needs further investigation once all study data are avail-
able for analysis. Fueled by the HIV epidemic, TB case
notification rates in Botswana increased from about 202/
100,000 population in 1990 to about 600/100,000 in
1998, plateaued at this level during 1998 through 2007,
and have since declined to about 470/100,000 in recent
years [36]. Increased ART coverage among HIV-infected
persons might again explain declining national TB inci-
dence and the lower-than-expected TB prevalence
among HIV clinic enrollees in this study [53]. In retro-
spect, the protocol-specified large sample sizes and
resulting high pre-study power to answer the first two
primary study questions, were important precautions in
place to ensure any sample size shortfalls did not result
in trial futility.
Although, several Xpert impact studies have been pub-
lished after this trial started, the two key study questions
have not yet been answered. Firstly, data validating the
Botswana Xpert diagnostic algorithm have not yet been re-
ported, and this is an important program evaluation activity
[54]. Secondly, among six trials that have compared all-
cause mortality outcomes of study enrollees between
microscopy and Xpert arms [17, 21, 54–57], none have ob-
served Xpert impact on either morbidity or mortality out-
comes, and only one was conducted exclusively among
ART enrollees (Mupfumi et al) [21]. Certain study limita-
tions of the trial by Mupfumi et al, including small sample
size (N = 424) and powering the study to detect differences
in a composite outcome (death or TB) between study arms,
mean that XPRES, with its larger sample size (N = 16,267)
and powered to detect Xpert impact on 6-month mortality
rates specifically, is still positioned to provide a valuable sci-
entific contribution. In addition, the intervention in XPRES
is different from interventions employed in previous Xpert
impact trials [17, 21, 54–59]—it represents a package of
strengthened ICF interventions, activation of the Xpert de-
vice, and improved tracing for patients late for ART clinic
appointments. In real-world settings, ICF interventions are
often implemented at a sub-optimal level of quality and
consistency due to health system weakness [9], and
strengthening health systems to improve ICF compliance is
arguably as important as the rollout of a new TB diagnostic
device [17]. In addition, preventing treatment interruptions
or LTFU during early ART through the tracing interven-
tion, could contribute to reductions in all-cause, 6-month
ART mortality rates [42, 43].
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